IL-NIELSENIQ
NielsenIQ (NIQ), the world leader in measurement and data analytics, is excited to announce that ‘NIQ Ask Arthur’- a groundbreaking GenAI-driven tool—has been integrated into NIQ Discover. This transformative solution offers AI-guided global search and personalized recommendations, streamlining data analysis and facilitating informed decision-making. Launching “NIQ Ask Arthur” marks an important milestone for NIQ Labs. Positioned as an innovation powerhouse, NIQ Labs is ready to accelerate the future of innovation by solving client problems and uncovering new pathways to growth. Coupled with investments, NIQ Labs taps into an extensive array of data assets, employing intuitive business intelligence tools and predictive analytics driven by generative AI (GenAI) and authoritative data science pioneering the next era of inventive products.
With conversational AI features, ‘NIQ Ask Arthur’ empowers users to delve deeper into datasets, revolutionizing data-driven choices and showcasing NielsenIQ's commitment to cutting-edge analytics.
NIQ Discover, a state-of-the-art data visualization solution, accelerates access to insights for CPG manufacturers and retailers. It creates fresh, user-friendly pathways to insights, leveraging the power of on-demand data across multiple data sets. NIQ Discover is designed to help CPG manufacturers and retailers get meaningful insights faster, and measure and track what’s most important to their business within a single, centralized platform.
NIQ Ask Arthur in NIQ Discover enables enhanced insights discovery, so users can efficiently uncover valuable information, enriching the brand story and democratizing data access. Current and new users can uncover meaningful information, trends, and patterns that may otherwise go unnoticed, leading them to the most relevant areas of analysis. At NIQ we provide the Full View™, and we maintain the highest standard of data accuracy and quality. GenAI will help NIQ Discover users decipher diverse formats and tackle complex business questions.
“The vision of leveraging AI to assist in data analysis and storytelling is incredibly powerful. Democratizing access to data and analytics is crucial in helping users make informed decisions and drive innovation. ‘NIQ Ask Arthur’ unlocks the power of analytics on the Discover platform,” says Troy Treangen, Chief Product Officer, NIQ.
NIQ Ask Arthur in Discover enables users to save time by proactively suggesting insights and simplifying data navigation through a seamless, conversational AI-powered experience.
With NIQ’s investment in the cutting edge NIQ Discover platform, combined with our diverse data types and deep industry expertise, NIQ Ask Arthur delivers unparalleled value to clients.
NIQ is best positioned to understand data and the business questions that help brands unravel their story. The company’s agility and rapid deployment strategies have facilitated remarkable technological advancement. In the past year, the NIQ Discover platform witnessed extraordinary growth, surging from 2,500 users in January 2023 to an impressive 40,000 across 71 countries today, showcasing the vast scale of NIQ’s technological expansion. This ability to rapidly deploy technology, enhance user engagement, and establish a global presence underscores NIQ’s unparalleled agility and innovation in the tech industry. These advancements facilitate accelerated insights across diverse industries, channels, and products, driving speed-to-insight at an unprecedented scale to deliver the Full View™.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in 95+ countries representing 97% of the world’s GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513168921/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)24.2.2025 00:50:00 CET | Press release
Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab) is approved by the European Commission (EC) for all indications of the reference product1 EC approval is based on a comprehensive data package demonstrating Avtozma®’s biosimilarity to RoActemra®2,3 Celltrion’s biosimilar portfolio continues to grow, expanding treatment options to meet the needs of people with immune diseases Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA).1 The approval further strengthens Celltrion’s growing immunology portfolio. “Today’s approval of Avtozma®, a biosimilar to RoActemra®, marks a critical step i
Andersen lancerer global rådgivningspraksis på seks kontinenter og skaber forandring i virksomheder22.2.2025 22:20:00 CET | Pressemeddelelse
Andersen Consulting kombinerer digital transformation og AI-drevne løsninger med Andersen Globals brancheførende ekspertise inden for skat, jura, værdiansættelse og global mobilitet Andersen fornyr landskabet inden for professionelle tjenester med lanceringen af Andersen Consulting, som er en global rådgivningsvirksomhed, der integrerer innovative forretningsstrategier, digital transformation og AI-drevne teknologiløsninger med Andersen Globals brancheførende ekspertise inden for skat, jura, værdiansættelse og global mobilitet. Andersens gnidningsfri tilgang er et uafhængigt alternativ til traditionelle rådgivningsvirksomheder ved at sætte kundens tilfredshed som målestok for vores succes. En ny æra med AI-dreven, flerdimensionel rådgivning Moderne virksomheder står overfor komplekse globale udfordringer, der kræver mere end traditionelle rådgivningstjenester. Andersen Consulting tilbyder en gnidnigsfri, flerdimensionel tilgang, der kombinerer ekspertise inden for virksomhedsforandring
Alpha Blue Ocean Group Announces the Launch of its Investment Banking Service Provider Division: ABO Transaction Advisory Services. Pierre Vannineuse Steps Down as CIO of ABO’s Investment Division to Lead ABO Transaction Advisory Services Full Time21.2.2025 15:00:00 CET | Press release
ABO Group, a market leader in Europe for PIPE deals and complex public cross border M&As, announces the establishment of Alpha Blue Ocean Transaction Advisory Services LTD ("ABO-TAS"), a new division dedicated to offering Public Listing Advisory, Capital Raise Advisory, Non-Deal Roadshows, M&A, Management Consulting, Restructuring Advisory and other transaction advisory services. ABO TAS is fully segregated and separate from the Alpha Blue Ocean Group’s Investment Division (which carries out the traditional investment activities of the ABO Group). ABO Group’s investment banking services will leverage the decades of combined experience of the ABO TAS team in investment banking, Public ECM and DCM and most notably structured PIPEs and complex cross border transactions. On the consulting side, the ABO TAS team is dedicated to help businesses reach their maximum potential by capturing synergies between companies and its broad network of established relationships. To spearhead this initiati
Erectile Dysfunction: The PelviTouch Revolution Comes From DEKA’s Italian Technology21.2.2025 14:30:00 CET | Press release
DEKA Laser, a subsidiary of El.En. S.p.A., a company operating in the Laser and Energy-Based Devices market, listed on Borsa Italiana’s Euronext STAR Milan (“STAR”), and a global leader in medical technologies, has presented its latest innovative therapy, PelviTouch, for the treatment of erectile dysfunction, at the European Society for Sexual Medicine (ESSM) congress. This technology was initially developed, with great success, for the treatment of urinary incontinence for both sexes, and it has now been optimized and specialized by DEKA’s research and development team to improve men’s intimate health, with effective treatments aimed specifically at erectile dysfunction, a field in which the Italian company is an absolute pioneer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221055364/en/ PelviTouch Therapy Presentation at ESSM Congress (Photo by DEKA) Paolo Salvadeo, DEKA’s CEO and El.En. S.p.A.’s General Manager, has
REPLY: Go Reply and Sprint Reply Automate the Creation of Clinical Study Reports for Dr. Willmar Schwabe with AI21.2.2025 11:01:00 CET | Press release
Go Reply, a leading Google Cloud Premier Partner, together with Sprint Reply, the Reply Group’s expert in strategic consulting and digital transformation, has developed an AI-driven tool for the pharmaceutical company Dr. Willmar Schwabe that streamlines the preparation of clinical study reports and ensures compliance with the highest scientific standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221805824/en/ By combining Go Reply's expertise in Google technologies with Sprint Reply’s ability to transform business models, a cutting-edge solution has been created that allows Dr. Willmar Schwabe's team to focus on what really matters: advancing research for innovative medicines to improve public health. (Graphic: Business Wire) To obtain marketing authorisation for its high-quality herbal drugs, Dr. Willmar Schwabe must rigorously test their efficacy, safety and tolerability in clinical trials. By leveraging the powe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom